Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.
Yahiaoui S, Hamidouche K, Ballandonne C, Davis A, de Oliveira Santos JS, Freret T, Boulouard M, Rochais C, Dallemagne P. Yahiaoui S, et al. Among authors: davis a. Eur J Med Chem. 2016 Oct 4;121:283-293. doi: 10.1016/j.ejmech.2016.05.048. Epub 2016 May 26. Eur J Med Chem. 2016. PMID: 27266998
Novel multitarget-directed ligands targeting acetylcholinesterase and σ1 receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase.
Lalut J, Santoni G, Karila D, Lecoutey C, Davis A, Nachon F, Silman I, Sussman J, Weik M, Maurice T, Dallemagne P, Rochais C. Lalut J, et al. Among authors: davis a. Eur J Med Chem. 2019 Jan 15;162:234-248. doi: 10.1016/j.ejmech.2018.10.064. Epub 2018 Nov 8. Eur J Med Chem. 2019. PMID: 30447434
A Novel in vivo Anti-amnesic Agent, Specially Designed to Express Both Acetylcholinesterase (AChE) Inhibitory, Serotonergic Subtype 4 Receptor (5-HT4R) Agonist and Serotonergic Subtype 6 Receptor (5-HT6R) Inverse Agonist Activities, With a Potential Interest Against Alzheimer's Disease.
Hatat B, Yahiaoui S, Lecoutey C, Davis A, Freret T, Boulouard M, Claeysen S, Rochais C, Dallemagne P. Hatat B, et al. Among authors: davis a. Front Aging Neurosci. 2019 Jun 19;11:148. doi: 10.3389/fnagi.2019.00148. eCollection 2019. Front Aging Neurosci. 2019. PMID: 31316368 Free PMC article.
Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease.
Chrétien B, Jourdan JP, Davis A, Fedrizzi S, Bureau R, Sassier M, Rochais C, Alexandre J, Lelong-Boulouard V, Dolladille C, Dallemagne P. Chrétien B, et al. Among authors: davis a. Br J Clin Pharmacol. 2021 Jul;87(7):2830-2837. doi: 10.1111/bcp.14690. Epub 2020 Dec 23. Br J Clin Pharmacol. 2021. PMID: 33274491 Free article.
Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer's disease.
Toublet FX, Lalut J, Hatat B, Lecoutey C, Davis A, Since M, Corvaisier S, Freret T, Sopková-de Oliveira Santos J, Claeysen S, Boulouard M, Dallemagne P, Rochais C. Toublet FX, et al. Among authors: davis a. Eur J Med Chem. 2021 Jan 15;210:113059. doi: 10.1016/j.ejmech.2020.113059. Epub 2020 Dec 3. Eur J Med Chem. 2021. PMID: 33310288
6,517 results